牛牛AI助手已提取核心信息
Vertex Pharmaceuticals Inc. officer Stuart A. Arbuckle is set to sell 4,804 shares of common stock on 02/20/2024, with an aggregate market value of approximately $2,021,475. The shares to be sold were recently acquired on 02/17/2024, through restricted stock vesting and performance shares, both as part of compensation from the issuer. This transaction follows a recent history of sales by Arbuckle over the past three months, totaling 12,898 shares for gross proceeds of $5,237,527.8.
Vertex Pharmaceuticals Inc. officer Stuart A. Arbuckle is set to sell 4,804 shares of common stock on 02/20/2024, with an aggregate market value of approximately $2,021,475. The shares to be sold were recently acquired on 02/17/2024, through restricted stock vesting and performance shares, both as part of compensation from the issuer. This transaction follows a recent history of sales by Arbuckle over the past three months, totaling 12,898 shares for gross proceeds of $5,237,527.8.
Vertex Pharmicals Inc.高管斯图尔特·阿巴克尔定于2024年2月20日出售4,804股普通股，总市值约为2,021,475美元。拟出售的股票最近于2024年2月17日通过限制性股票归属和绩效股票收购，这两者都是发行人薪酬的一部分。该交易遵循了Arbuckle在过去三个月中的近期销售记录，共计12,898股股票，总收益为5,237,527.8美元。
Vertex Pharmicals Inc.高管斯图尔特·阿巴克尔定于2024年2月20日出售4,804股普通股，总市值约为2,021,475美元。拟出售的股票最近于2024年2月17日通过限制性股票归属和绩效股票收购，这两者都是发行人薪酬的一部分。该交易遵循了Arbuckle在过去三个月中的近期销售记录，共计12,898股股票，总收益为5,237,527.8美元。
有用
没用